The announcement that a draft Brexit deal has been negotiated between the UK and the EU and agreed by the UK Cabinet was greeted with some relief by the life sciences industry as offering a degree of certainty for the sector, not least because of the proposed transition period in the agreement that would avoid a “cliff-edge” Brexit in March next year.
It is far from clear whether the draft agreement will in fact become the final deal, but Mike Thompson, CEO...







